France Concerned About The Use Of CRISPR In Vegetables
CRISPR Brought Under GMO Rules By French Administrative Court
CRISPR Brought Under GMO Rules By French Administrative Court
Influenza B Protein Structure – MIT Chemists Reveal the Protein Structure
Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda Pharmaceutical.
A U.S. bankruptcy court has given groups interested in buying antibiotic biotech Melinta Therapeutics until March 2 to make an offer. The bidding process creates an opportunity for Melinta’s business to continue as a going concern despite its financial difficulties.
CICC Capital has raised a RMB 1.6 billion ($229 million) biologic investment fund. The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing target.
In its fourth-quarter earnings out early Friday morning, U.K.-based Big Pharma AstraZeneca has cut two early-stage experimental meds.
A startup has raised $12 million to fund its real-time system for monitoring patients undergoing dialysis at home and calling in potential complications.
The FDA has accepted Bristol-Myers Squibb’s lisocabtagene maraleucel for priority review, setting the stage for a mid-August decision on whether to approve the CAR-T therapy. Bristol-Myers arrives at the FDA with data to suggest the cell therapy can hold its own against Gilead’s Yescarta and Novartis’ Kymriah.
Ipsen has recorded a €669 million ($728 million) partial impairment on a rare disease drug it bought last year. The prospects of the drug, palovarotene, took back-to-back hits around the end of 2019, leading Ipsen to dramatically dial down its expectations.
Deciphera Pharmaceuticals has been handed a priority review from the FDA for its cancer drug ripretinib.